Purpose / DescriptionIn this phase 3 open-label trial, 703 noncirrhotic adults with genotype 1 HCV infection were randomized to receive either 8 or 12 weeks of glecaprevir-pibrentasvir; 38% were treatment-experienced (3 were sofosbuvir experienced and the remainder interferon experienced). Among those enrolled 33 were coinfected with HIV. The sustained virologic response rate (SVR12) was 99% for the 8-week arm and 99.7% for the 12-week arm, and the SVR rate remained high in persons with HIV coinfection, prior treatment experience, and baseline resistance-associated substitutions.